BioNTech

BioNTech的转型十字路口：业绩承压与帅印交接并行，肿瘤管线成胜负手

BioNTech的转型阵痛期：业绩滑坡、帅印交接与百亿现金储备的三重奏

angelina -

BioNTech的至暗时刻：三重重压之下，新帅能否重塑增长叙事？

BioNTech权力交接倒计时：新帅2027年掌舵，千亿现金能否撑过转型深水区？

angelina -

BioNTech’s Summer of Upheaval: A New Captain, a Cut Forecast, and a 16.6 Billion Euro Anchor

angelina -

BioNTech’s Oncology Bet Faces Its Moment of Truth as COVID Cash Fades

angelina -

BioNTech的“死亡之谷”跨越战：16.6亿欧元现金储备与肿瘤管线的赛跑

angelina -

BioNTech的双重考验：千亿回购与专利诉讼夹击下，新帅能否带领转型突围？

kashif hafeez -

BioNTech’s Twin Transitions: A New Chief Executive and a Pipeline Poised for Proof

angelina -

BioNTech’s Buyback Can’t Lift the Stock — Now the August 4 Numbers Have to Do the Heavy Lifting

Brett Shapiro -

BioNTech的“价值陷阱”疑云：16.8亿欧元现金与肿瘤管线，市场为何仍在观望？

BioNTech的十字路口：疫苗现金牛与肿瘤野心的双重博弈

BioNTech’s Legal Crossfire and Vaccine Pipeline Converge on a Pivotal Earnings Moment

kashif hafeez -

BioNTech双线布局：BMS加码商业化押注，XFG疫苗获批能否撑起Q4盈亏平衡？

BioNTech财报前夕突获欧盟放行：XFG疫苗获批上市，肿瘤转型与专利诉讼交织成多空博弈焦点

Brett Shapiro -
123...13Page 1 of 13